0001567619-21-012641.txt : 20210628
0001567619-21-012641.hdr.sgml : 20210628
20210628105340
ACCESSION NUMBER: 0001567619-21-012641
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210609
FILED AS OF DATE: 20210628
DATE AS OF CHANGE: 20210628
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schutte John
CENTRAL INDEX KEY: 0001713580
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10113
FILM NUMBER: 211050967
MAIL ADDRESS:
STREET 1: 9707 SHELBYVILLE ROAD
CITY: LOUISVILLE
STATE: KY
ZIP: 40233
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACURA PHARMACEUTICALS, INC
CENTRAL INDEX KEY: 0000786947
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 110853640
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 616 N. NORTH COURT, SUITE 120
CITY: PALATINE
STATE: IL
ZIP: 60067
BUSINESS PHONE: 847-705-7709
MAIL ADDRESS:
STREET 1: 616 N. NORTH COURT, SUITE 120
STREET 2: .
CITY: PALATINE
STATE: IL
ZIP: 60067
FORMER COMPANY:
FORMER CONFORMED NAME: HALSEY DRUG CO INC/NEW
DATE OF NAME CHANGE: 19920703
4
1
doc1.xml
FORM 4
X0306
4
2021-06-09
0
0000786947
ACURA PHARMACEUTICALS, INC
ACUR
0001713580
Schutte John
2604 RIVER GREEN CIRCLE
LOUISVILLE
KY
40206
0
0
1
0
Common Stock
8912655
D
Common Stock
2021-06-09
4
C
0
42984375
0.16
A
42984375
I
By Abuse Deterrent Pharma, LLC
Warrant to Purchase Common Stock
0.528
2017-07-24
2022-07-23
Common Stock
1782531
1782531
D
Warrant to Purchase Common Stock
0.01
2019-06-28
2024-06-28
Common Stock
10000000
10000000
I
By Abuse Deterrent Parma, LLC
Convertible Promissory Note
0.16
2021-06-09
4
C
0
6877500
0
D
2019-06-28
Common Stock
42984375
0
I
By Abuse Deterrent Parma, LLC
The Reporting Person is the manager and a member of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of the securities, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
On the conversion date, $6,000,000 of principal and $877,500 of interest under the note was converted into the Issuer's common stock. For each $0.16 converted, AD Pharma received one share of common stock.
This note is convertible, at the election of AD Pharma, at any time prior to repayment of the note and matures on July 1, 2023.
/s/ John Schutte
2021-06-24